Internal Medicine, Endocrinology, Diabetes, & Metabolism · Melbourne, FL
NPI
1427057256
Since 2005
Specialty
Internal Medicine, Endocrinology, Diabetes, & Metabolism
Code 207RE0101X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
2290 W Eau Gallie Blvd, Suite 100
Melbourne, FL, 32935
Phone (321) 309-9000
Groups this clinician bills Medicare through
Medicare paid, 2024
$865K
51,333 services
Medicare patients, 2024
3,839
Average age 75
Drug cost, 2024
$3.3M
8,044 prescriptions
Company payments, 2025
$1,528
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rajesh K Desai was code 36415 (venipuncture blood collection), 5,096 times for 2,313 patients. In total Rajesh K Desai billed 51,333 services in 168 codes, and Medicare paid $865K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-01-19.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 36415 Venipuncture Blood Collection | Office | 5,096 | 2,313 | $8.64 | $44K |
| J0897 Injection, denosumab, 1 mg | Office | 4,800 | 46 | $20.49 | $98K |
| 80053 Clinical Chemistry | Office | 4,691 | 2,355 | $10.28 | $48K |
| 80061 Clinical Chemistry | Office | 3,768 | 2,090 | $13.03 | $49K |
| 85025 Blood Count | Office | 3,309 | 1,954 | $7.57 | $25K |
| 84443 Clinical Chemistry | Office | 3,234 | 1,890 | $16.39 | $53K |
| 83036 Blood Count | Office | 3,112 | 1,578 | $9.44 | $29K |
| 84439 Clinical Chemistry | Office | 2,139 | 1,287 | $8.79 | $19K |
| 83721 Clinical Chemistry | Office | 1,537 | 950 | $10.18 | $16K |
| 82607 Clinical Chemistry | Office | 1,261 | 815 | $14.69 | $19K |
| 82306 Clinical Chemistry | Office | 1,215 | 854 | $28.90 | $35K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,057 | 697 | $12.64 | $13K |
| 71250 CT/CTA - Chest | Office | 1,017 | 360 | $43.52 | $44K |
| 82043 Clinical Chemistry | Office | 992 | 665 | $5.63 | $5,582 |
| 82570 Clinical Chemistry | Office | 942 | 628 | $5.07 | $4,773 |
By year: 2022 $888K for 58,130 services; 2023 $886K for 54,004 services; 2024 $865K for 51,333 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 5,096 | 2,313 | $8.64 | $44K |
| 80053 Clinical Chemistry | 4,691 | 2,355 | $10.28 | $48K |
| 80061 Clinical Chemistry | 3,768 | 2,090 | $13.03 | $49K |
| 85025 Blood Count | 3,309 | 1,954 | $7.57 | $25K |
| 84443 Clinical Chemistry | 3,234 | 1,890 | $16.39 | $53K |
| 83036 Blood Count | 3,112 | 1,578 | $9.44 | $29K |
| 84439 Clinical Chemistry | 2,139 | 1,287 | $8.79 | $19K |
| 83721 Clinical Chemistry | 1,537 | 950 | $10.18 | $16K |
| 82607 Clinical Chemistry | 1,261 | 815 | $14.69 | $19K |
| 82306 Clinical Chemistry | 1,215 | 854 | $28.90 | $35K |
Medicare prescription drug claims, 2024
In 2024, the drug Rajesh K Desai prescribed most often to Medicare patients was Levothyroxine Sodium, with 691 prescriptions and refills. In total Rajesh K Desai wrote 8,044 Medicare prescriptions that cost $3.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Levothyroxine Sodium Generic | 691 | 1,949 | 195 | $9,310 |
| Synthroid Levothyroxine Sodium | 661 | 1,721 | 147 | $61K |
| Ozempic Semaglutide | 534 | 893 | 121 | $812K |
| Metformin Hcl Generic | 455 | 1,330 | 141 | $4,760 |
| Jardiance Empagliflozin | 397 | 806 | 98 | $464K |
| Atorvastatin Calcium Generic | 380 | 1,110 | 120 | $6,317 |
| Glimepiride Generic | 282 | 819 | 89 | $3,695 |
| Farxiga Dapagliflozin Propanediol | 272 | 557 | 74 | $296K |
| Rosuvastatin Calcium Generic | 266 | 778 | 96 | $4,618 |
| Mounjaro Tirzepatide | 255 | 330 | 57 | $343K |
| Repaglinide Generic | 253 | 697 | 88 | $14K |
| Novolog Flexpen Insulin Aspart | 221 | 472 | 71 | $45K |
| Tresiba Flextouch U-200 Insulin Degludec | 196 | 452 | 59 | $191K |
| Novolog Mix 70-30 Flexpen Insulin Aspart Prot/Insuln Asp | 164 | 327 | 40 | $43K |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 152 | 350 | 48 | $23K |
Brand drugs: 4,509 claims; generic drugs: 3,138 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rajesh K Desai $1,528 ($1,528 in general payments such as food, travel and fees) from 26 companies. The largest payer was Dexcom, Inc. with $148.
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. DXCM | 5 | $148 |
| Corcept Therapeutics CORT | 6 | $118 |
| Madrigal Pharmaceuticals MDGL | 4 | $115 |
| Novo Nordisk Inc NVO | 6 | $112 |
| Abbvie Inc. ABBV | 6 | $101 |
| Tandem Diabetes Care, Inc. TNDM | 3 | $100 |
| Amgen Inc. AMGN | 4 | $98.12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $94.21 |
| Neurocrine BioSciences, Inc. NBIX | 3 | $80.69 |
| Ascendis Pharma Endocrinology Inc ASND | 3 | $70.22 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.